Diabetes Mellitus, Type 2
Conditions
Keywords
Type 2 diabetes mellitus on Stable insulin therapy, Balaglitazone, Pioglitazone (Actos®), HbA1c, Weight gain, Oedema, Fasting blood glucose
Brief summary
Type 2 diabetes mellitus is a metabolic disorder that is primarily characterized by insulin resistance, relative insulin deficiency, and hyperglycemia. People with type 2 diabetes are at high risk of many serious diabetic complications, including cardiovascular disease, blindness, nerve damage and kidney damage. Balaglitazone is a thiazolidinedione derivative that is being developed as an oral anti-diabetic drug to improve blood glucose control in patients with type 2 diabetes. The purpose of this study is to assess if additional treatment with balaglitazone in patients with type 2 diabetes on stable insulin treatment will improve blood glucose control and decrease the daily insulin dose compared to placebo, but with less impact on weight gain and oedema than pioglitazone (Actos®) 45 mg.
Interventions
DRUGBalaglitazone
One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
Sponsors
Rheoscience A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Type 2 diabetes mellitus, being diagnosed according to the 1999 WHO criteria for at least 3 months 2. Age ≥ 18 years 3. BMI ≥ 25.0 kg/m2 4. HbA1c ≥ 7.0 % 5. Treatment with insulin with stable dose of at least 30 U/day (± 4 U/day), for at least 75 days
Exclusion criteria
1. Prior or current use of any PPAR-γ agonist 2. Recent use (\< 3 months) of an investigational drug 3. Pre-existing medical condition judged to preclude safe participation in the study 4. Contraindication/intolerance to study medication 5. Use of any drug which in the Investigator's opinion could interfere with the glucose level (e.g. systemic corticosteroids) 6. Diagnosed or receiving medication for heart failure, NYHA I to IV 7. Hospitalisation for a major CV event in the last 3 months, scheduled major CV intervention 8. Uncontrolled treated/untreated systolic blood pressure \>180 mmHg and/or diastolic blood pressure \> 95 mmHg 9. Known diabetic macular oedema 10. Hematuria 11. Serum creatinine \>130 μmol/l 12. ALT, AST, total bilirubin or alkaline phosphatase ≥ 2.5 times the upper limit of normal 13. Haemoglobin significantly (in the Investigators opinion, but not more than 1 mmol/L) below the lower limit of normal or haemoglobinopathy interfering with valid HbA1c assay 14. Pregnancy, breast feeding or planning pregnancy or not using adequate contraceptive methods (adequate contraceptive measures are an intrauterine device or oral contraceptives) 15. Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation 16. Abuse of alcohol or drugs, or presence of any condition that in the Investigators opinion may lead to poor adherence to study protocols 17. Cancer or any clinically significant disease or disorder, except for conditions associated to the type 2 diabetes, which in the Investigator's opinion could interfere with the results of the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c, fasting plasma glucose and 7-point plasma glucose profiles, weight gain, lower leg oedema and safety parameters. | baseline, 4, 8, 12, 17, 21 and 26 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Waist and hip circumferences, plasmaNT-proBNP, ECG, body composition as measured by DXA, blood lipid profiles, plasma insulin | baseline and 26 weeks |
Countries
Denmark
Outcome results
None listed